LAB Q1 2024 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q1 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$46M+81.3% YoY

Gross Profit

$24M53.1% margin

Operating Income

-$60M-132.2% margin

Net Income

-$32M-70.6% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+61.6%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$63M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$778M

Total Liabilities

$200M

Stockholders' Equity

$577M

Cash & Equivalents

$287M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$25M	+81.3%
Gross Profit	$24M	$12M	+97.0%
Operating Income	-$60M	-$17M	-262.7%
Net Income	-$32M	-$17M	-90.9%

Revenue Segments

Product And Service

$45M42%

Product

$24M22%

Service

$21M20%

Consumables

$10M10%

Instruments

$5M5%

Collaboration and Other Revenue

$921,0001%

Geographic Segments

Americas

$25M54%

EMEA

$13M27%

Asia Pacific

$8M18%